Defibrotide

Phase 3

Jazz Pharmaceuticals plc (JAZZ)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Drug Information

Target Indication

Severe Hepatic Veno-Occlusive Disease

Clinical Trial

NCT00358501

Last updated: 1/2/2026

Regulatory Approvals

EMA10/18/2013

Defitelio

Defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy. It is indicated in adults and in adolescents, children and infants over 1 month of age.

View on EMA

Developer

JAZZ

Jazz Pharmaceuticals plc

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

NabiximolsPhase 3

Pain

SativexPhase 3

Multiple Sclerosis

GWP42003-PPhase 3

Epilepsy

GWP42003-P 20 mg/kg/day DosePhase 3

Epilepsy

Sativex®Phase 3

Pain

View full pipeline